Infantile Spasms clinical trials at UCLA
3 in progress, 1 open to eligible people
Prevent Infantile Spasms Relapse
open to eligible people ages 2 months to 18 months
After initially successful treatment, many children with infantile spasms unfortunately have a relapse, and relapse is linked to poor long-term outcomes such as autism and other forms of epilepsy. The aim of this study is to determine if treatment with low-dose prednisolone is safe, well tolerated, and effective in reducing the risk of relapse.
Los Angeles 5368361, California 5332921
ZX008 in Subjects With CDKL5 Deficiency Disorder
Sorry, in progress, not accepting new patients
This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).
Los Angeles 5368361, California 5332921 and other locations
Treatment of Refractory Infantile Spasms With Fenfluramine
Sorry, not currently recruiting here
This is a phase II clinical trial in which children with refractory infantile spasms (also called epileptic spasms or West syndrome) will be treated with fenfluramine, to evaluate efficacy, safety, and tolerability. Patients with infantile spasms that have not responded to treatment with vigabatrin and ACTH we will be invited to participate. Study participants will undergo baseline video-EEG, receive treatment with fenfluramine for 21 days, and then undergo repeat video-EEG to determine effectiveness. Patients with favorable response will have the opportunity to continue treatment for up to 6 months.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Infantile Spasms research studies include Shaun A Hussain, MD.
Last updated: